REGN - REGENERON PHARMACEUTICALS, INC.
IEX Last Trade
716.9
7.590 1.059%
Share volume: 1,406,307
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$709.31
20.02
0.03%
Fundamental analysis
46%
Profitability
64%
Dept financing
24%
Liquidity
70%
Performance
28%
Performance
5 Days
2.87%
1 Month
-1.10%
3 Months
-29.32%
6 Months
-33.75%
1 Year
-23.52%
2 Year
-1.54%
Key data
Stock price
$716.90
DAY RANGE
$666.25 - $717.37
52 WEEK RANGE
$708.96 - $1,211.20
52 WEEK CHANGE
-$23.52
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Leonard S. Schleifer
Region: US
Website: regeneron.com
Employees: 11,900
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: regeneron.com
Employees: 11,900
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.
Recent news